Dong-E-E-Jiao Co. (000423) Q4 2024 earnings summary

Executive summary

• Achieved revenue of ¥5.92 billion in 2024, up 25.57% year-over-year, with net profit attributable to shareholders at ¥1.56 billion, up 35.29% year-over-year.

• Maintained strong market leadership in the traditional Chinese medicine (TCM) sector, focusing on high-quality development and innovation.

• Implemented the “1238” strategy, emphasizing dual growth drivers (pharmaceuticals and health consumer products) and industry chain integration.

Financial highlights

• Revenue: ¥5,920,785,955.41 (+25.57% YoY); Net profit attributable to shareholders: ¥1,557,000,775.65 (+35.29% YoY).

• Operating cash flow: ¥2,170,810,025.93 (+11.13% YoY); Basic and diluted EPS: ¥2.42 (+35.20% YoY).

• Gross margin for core products exceeded 73%, with significant growth in both production and sales volumes.

• Asset-liability ratio at 21.05% at year-end; cash reserves of ¥5.01 billion.

Outlook and guidance

• Focus on executing the “1238” strategy, aiming for high-quality, sustainable growth and further internationalization.

• Plans to expand product lines, accelerate R&D, and strengthen supply chain resilience.

• 2025 targets include continued revenue and profit growth, new product launches, and enhanced brand influence.